Adamed wins first round of legal battle against Eli Lilly

Domestic drug producer Adamed has won a case against American Eli Lilly in the regional court. Adamed was accused of violating the patent law in the process of producing a drug used to treat schizophrenia. Eli Lilly said it would appeal the verdict. "The regional court has refused us the right to defend our case, as all the evidence against Adamed was dismissed. This is a good basis to appeal. This will take another month," said Agnieszka Deeg-Dąbrowska, Eli Lilly's councilor. The American company also thinks that the process of registering the competing drug was not carried out properly. "This positive verdict is a chance for Adamed to develop. It also ensures access for over 10,000 patients to the drug and could lead to a fall in the prices of medicines treating schizophrenia," claims Adamed's president Maciej Adamkiewicz. (Puls Biznesu, p. 7) A.K.